Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma

Black, Charles T.; Cangır, Ayten; Choroszy, Mary; Andrassy, Richard J.

doi:10.1016/0022-3468(91)90676-k

Cited by 46 publications

(25 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin is one of the most active chemotherapy agents for HB (13) but is potentially nephrotoxic. Administration of this agent is challenging in this population with preexisting renal compromise.…”

Section: Discussionmentioning

confidence: 99%

A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although the principal predictor of hepatoblastoma survival is complete surgical resection, the majority of children present with initially unresectable Stage III tumors (North American Staging System) (2, 4-6). Nevertheless, the introduction of cisplatin-based therapies has achieved remarkably effective cytoreduction and greater delayed resectability (4, 7, 8). …”

mentioning

confidence: 99%

Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum α-fetoprotein kinetics

Lovvorn

Ayers

Zhao

et al. 2010

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Purpose Hepatoblastoma is commonly unresectable at presentation, necessitating induction chemotherapy before definitive resection. To refine the paradigm for timing of resection, we questioned whether a plateau in hepatoblastoma responsiveness to neoadjuvant therapy could be detected by calculating tumor volume (TV) and serum α-fetoprotein (sAFP) kinetics. Methods To calculate TV and sAFP as measures of treatment responsiveness over time, infants having initially unresectable epithelial-type hepatoblastomas were identified at a single institution (1996-2008). Effects of therapy type, therapy duration, and lobe of liver involvement on TV, sAFP, margin status, and toxicity were analyzed. Results Of 24 infants treated for epithelial-type hepatoblastoma during this interval, 5 were resected primarily, and 15 had complete digital films for kinetics analysis. Both TV and sAFP decreased dramatically over time (p<0.0001). No statistically significant difference in mean TV or sAFP was detected after chemotherapy cycle 2. Left lobe tumors had greater presenting levels of and significantly slower decay in sAFP compared to right lobe tumors (p=0.005), although no statistically significant differences in TV existed between liver lobes. Resection margins did not change with therapy duration. Conclusions Measuring TV and sAFP kinetics accurately reflects hepatoblastoma responsiveness to induction therapy. Treatment toxicities may be reduced by earlier resection and tailoring of chemotherapeutic regimens.

show abstract

“…3 Subsequently, preoperative chemotherapy for unresectable hepatoblastoma became the only effective method in rendering these tumors resectable. [4][5][6][7][8] Five of our patients with unresectable hepatoblastoma who had preoperative chemotherapy followed by surgical resection are alive and well, and in one, there was total tumor disappearance with chemotherapy only. In all of the patients, there was a significant shrinkage of the tumor which made it easier to resect.…”

Section: Discussionmentioning

confidence: 87%

“…3 Such cases judged intraoperatively or by preoperative radiological investigations should be treated with preoperative chemotherapy in an attempt to shrink the tumor and to make it resectable. [4][5][6][7][8] A survey of the Surgical Section of the American Academy of Pediatrics in 1974 has shown that none of 51 children with unresectable hepatoblastoma was cured. 3 Subsequently, preoperative chemotherapy for unresectable hepatoblastoma became the only effective method in rendering these tumors resectable.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unresectable Hepatoblastoma: The Role of Preoperative Chemotherapy

et al. 1999

View full text Add to dashboard Cite

Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma

Cited by 46 publications

References 4 publications

A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature

A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature

Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum α-fetoprotein kinetics

Unresectable Hepatoblastoma: The Role of Preoperative Chemotherapy

Contact Info

Product

Resources

About